- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Lawrence Shulman, MD: Preparing for Biosimilar Trastuzumab
Lawrence Shulman, MD, deputy director for clinical services and director of the Center for Global Cancer Medicine at the Abramson Cancer Center at the University of Pennsylvania, discusses the arrival of biosimilar trastuzumab.
Transcript:
Trastuzumab has been one of the great advances in breast cancer care over the last several decades. When it was approved in 2005 as an adjuvant therapy for patients who had HER2-positive breast cancer, the mortality rate for those patients went down by almost 50%. There are very few things that we’ve done in cancer medicine that have had such a dramatic effect on overall survival.
But it’s a very expensive drug, and the estimates are that it’s about $40,000 for a course of adjuvant therapy, and that’s a strain on the health system and it’s certainly a strain on patients and their families as well.
Biosimilars have started to come on the market, and I think they’ve been brought on the market very responsibly. The companies have done good trials to show that the effectiveness and the toxicity protocols and profiles are equivalent to what we’re seeing with the native Herceptin from Roche and Genentech. On the other hand, the biosimilars have not dropped the price substantially.
While we’re anxious to see them come on the market and we’re looking forward to competition driving the price down some, we’ve really not seen that effect yet in the [United States] or elsewhere in the world.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
